Drug intelligence / Profile preview

Total alkaloids from Gelsemium elegans Benth.

Development stage: Phase 1
Modality: Small Molecules
Administration: Subcutaneous, Intracerebroventricular

Overview

Total alkaloids from Gelsemium elegans Benth. (TAG) is a natural product extract derived from the plant Gelsemium elegans Benth. It has demonstrated anti-hepatocellular carcinoma (HCC) activity both in vitro and in vivo. Its mechanism of action involves inhibiting the proliferation of various tumor cells, including SMMC-7721, HepG2, H22, CAL27, MCF7, HT29, and HCT116, and promoting apoptosis. The inhibitory effect of TAG on HCC is linked to the regulation of the key gene CXCL13.

Targets

CXCL13 (C-X-C motif chemokine ligand 13)

Beyond the preview

Go deeper on Total alkaloids from Gelsemium elegans Benth..

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Total alkaloids from Gelsemium elegans Benth..

Explore the full profile